A Phase Ib Randomised, Controlled, Single-blind Study to Assess the Safety, Immunogenicity of the Malaria Vaccine Candidate R21 With Matrix-M1 Adjuvant in West African Adult Volunteers
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Jun 2017
At a glance
- Drugs R 21 (Primary) ; Matrix M
- Indications Malaria
- Focus Adverse reactions
- 19 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Jan 2018.
- 19 Jun 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2018.
- 19 Jun 2017 Status changed from recruiting to active, no longer recruiting.